Products

API

Our API – Other Pharmerging Markets Portfolio** consists of the following: Please Note - PhM DMF are shared on basis of customer request
Therapeutic Category Name of API
Anti-cancer Anastrozole
Azacitidine
Afatinib dimaleate
Bicalutamide
Belinostat
Bortezomib
Busulfan
Cabazitaxel
Carboplatin
Carfilzomib
Decitabine
Docetaxel Trihydrate
Docetaxel anhydrous
Erlotinib
Gefitinib
Gemcitabine HCl
Gemcitabine HCI (Alternate process)
Irinotecan Hydrochloride Trihydrate
Ibrutinib
Letrozole
Oxaliplatin
Paclitaxel Semi-synthetic
Pemetrexed Diacid
Ribociclib Succinate
Bendamustine Hydrochloride
Alectinib HCl
Plerixafor
Imatinib Mesylate
Neuromuscular Reversal Drug Sugammadex Sodium
Anesthetics Bupivacaine Hydrochloride
Levobupivacaine Hydrochloride
Ropivacaine Hydrochloride Monohydrate
Ropivacaine Hydrochloride Anhydrous
Antibiotic Chloramphenicol hemisuccinate

**The buyer / customer should make their independent evaluation of the patent scenario for their respective markets, in respect of the API/formulations bought from Fresenius Kabi Oncology Limited, and they shall be solely and exclusively responsible for all patent related liabilities including any litigation by third party.

Fresenius Kabi Oncology Ltd. do not intend to manufacture any product commercially until there is a valid IP. Listing of product shall not be construed in any way that Fresenius Kabi Oncology has violated any IP laws of the land.

 

© All Copyright Reserved | Fresenius Kabi Oncology Limited 2012-2018